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The genetic cause of significant disorders like Down syndrome (DS) and 
Duchenne muscular dystrophy (DMD) is well documented.  Pulmonary arterial 
hypertension (PAH), a co-morbid condition, is tied to mortality among these groups.  If 
undetected or untreated, in DS, this condition can lead to complications with coronary 
and lung disease later in life.  If undetected or untreated in DMD it can hasten the 
inevitable prognosis of the disease.  Individuals with the ability to communicate their 
symptoms and actively participate in treatment are at an advantage with subsequent 
benefit.  DS and DMD significantly decrease physical ability and communication 
capacity. 
Genetic research has allowed for earlier identification of, or predisposition for, the 
development of PAH.  Work has also progressed toward manipulation at the genetic level 
to decrease the severity and even eradicate the cardiopulmonary disorder.  This 
information is beginning to be applied in treatment for individuals with PAH.  The 
purpose of this scholarly project is to identify the research, prediction methods and 
treatment of PAH in individuals with Duchenne muscular dystrophy (DMD) and Down 
syndrome (DS) as it relates to decreased mortality or increased life expectancy among 
those groups.  The results showed significant gains in the understanding of PAH, DS and 
DMD individually.  There was little evidence of research focusing on PAH as it pertains 
particularly to DS or DMD.  Original studies were sought as a priority in the development 
of this work.  Some meta-analysis studies were included to further develop the expert 
opinion recommendations for treatment.  Keyword searches and sub-heading searches 
were performed within the PUBMED and CLINAHL databases. 
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The exchange of carbon dioxide and oxygen at the alveolar level is an intricate 
process.  An exacting balance is struck within the cardiopulmonary circuit to maintain 
pH, temperature and pressure.  The human body’s ability to buffer such imbalance is 
extraordinary.  Most problems that arise can be corrected with minor physiologic changes 
to the system.  Unfortunately, some imbalances result in workload discrepancies for 
constituents of the system.  One such discrepancy leads to increased pressure in the 
pulmonary arteries.   
Pulmonary arterial hypertension (PAH) is one of five forms of pulmonary 
hypertension (Tonelli et al., 2013).  PAH can take on one of several forms. 
The 5th World Symposium on Pulmonary Hypertension, that was held in Nice, France, 
February 27 to March 1, 2013, identifies four specific types of PAH:  Idiopathic, 
Familial, Drug or Toxin Induced and Associated.  Idiopathic PAH (IPAH) causes are 
unknown (Saji, 2014).  Familial PAH (FPAH) has a genetic cause (Chew, Loyd & 
Austin, 2017).  Drug or Toxin Induced PAH is a growing concern (Peacock, Murphy, 
McMurray, Baballero & Stewart, 2007). The most common type of PAH, associated 
(APAH), and occurs along with or by other medical conditions (Chew et al., 2017) 
Recent studies have provided insight in the diagnosis and screening for both 
familial and associated pulmonary arterial hypertension.  Research has led to earlier 
diagnosis of and screening for PAH (Tonelli et al., 2013).  Unfortunately, co-morbid 
and/or exacerbating conditions often dictate patient outcome (Tonelli et al., 2013).  Many 
disorders of the body cause APAH.  Two genetic conditions that have co-morbid 
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occurrence of APAH are Down syndrome and Duchenne muscular dystrophy.  Both of 
these disorders have high mortality rates.  
Statement of the Problem 
Identifying the specific underlying pathophysiology and etiology of PAH when 
associated with DMD and DS is vitally important to treatment.  It is also important to 
understand the options with proven, evidenced-based modalities particular to co-morbid 
conditions can have positive influence on patient outcomes from increased life 
expectancy to improved quality of life.  Reviewing what research has been completed 
helps deepen the understanding of the direction future investigation in PAH is taking.  
Statement of the Research Questions 
What is the correlation between genetic disorders like DMD and DS with 
increased incidence of PAH?  What has current and existing research shown in the 
understanding of pulmonary arterial hypertension?  What is the recommended, evidence 
based treatment modality for PAH specific to DMD and DS?  Among individuals with 
Duchenne muscular dystrophy and Down syndrome with co-morbid pulmonary arterial 
hypertension (PAH) has early recognition and treatment through genetic discovery, lead 
to a statistically significant increase in life expectancy versus previously undiagnosed or 
unrecognized PAH? 
REVIEW OF LITERATURE 
 
Research Methods  
 
In finding sources for the topic three medical research databases were used. 
PubMed, Medscape and CINAHL provided for ease of search term manipulation and 
consistent operation. Of the three, PubMed and CINAHL resulted in the majority of 
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found sources. The search for sources began with an article entitled “Cardiopulmonary 
Support in Duchene Muscular Dystrophy,” by J. Finsterer, 2006, Lung, 184(4), p. 205-
215. With the exception of this article, all sources were published within the last ten 
years. Initial keyword searches helped develop more focused subject headings later on. 
The initial keyword searches included terms like: pulmonary hypertension and Duchene 
muscular dystrophy, pulmonary hypertension and Down syndrome, Duchenne muscular 
dystrophy and cause of death, Down syndrome and cause of death. From the keyword 
search 4-5 articles were chosen and the subject headings were scrutinized to develop a 
more specific search. The subject heading search used terms like: BMPR2 and Duchene 
and congenital heart disease, pulmonary arterial hypertension and congenital heart 
disease, advanced therapy and Duchenne, therapies and Down syndrome, Down 
syndrome and nitric oxide and pulmonary hypertension, trisomy 21 and congenital heart 
defect, epigenetic and pulmonary arterial hypertension, pulmonary hypertension and 
DNA methylation, Down syndrome and congenital heart disease, pulmonary 
hypertension and BMPR2. From these searches, 68 articles were found. Articles were 
scrutinized for reputation of publication and pertinence to topic. Of the 68, 20 where 
chosen. 26 articles were excluded based on sample sizes less than 20 participants.  31 
articles were excluded as they were meta-analysis involving information from greater 
than 30 years ago.  Eleven studies on pulmonary hypertension related to genetic disorders 
were excluded as they were not specific to PAH. The remaining 20 articles provide 
credence and deeper understanding toward the research topic.  Three additional resources 
were added that included information that is greater than ten years old, as they provide 
insight into the foundation of understanding as well as perspective toward the advances 
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that have occurred. 
Pathophysiology of Pulmonary Arterial Hypertension (PAH): 
 
In the normal cardiopulmonary cycle, de-oxygenated blood is pumped by the right 
ventricle of the heart to the lungs through the pulmonary arteries.  Pressure in the 
pulmonary arteries is maintained at an average of 25 mmHg (Elliott, 2013).  This force is 
necessary to support gas exchange between the capillaries and alveoli of the lungs. The 
pressure in the pulmonary arteries will rise in order to overcome any force working 
against it.  When pressure chronically exceeds this average, undue stress is placed on the 
heart often resulting in right-sided heart failure (Tonelli et al., 2013).  
PAH is a disease of vascular tissue of the pulmonary system.  The disease 
progresses rapidly.  It is defined hemodynamically as a mean arterial pressure (mPAP) > 
25 mmHg and pulmonary capillary wedge pressure (PCWP) of < 15 mm Hg.  PAH is 
characterized by destructive vascular changes that include:  inflammation, 
vasoconstriction, cell proliferation, hypertrophy and (in severely symptomatic patients) 
formation of plexiform lesions (Archer, Weir & Wilkins, 2010).  Progression of these 
structural changes eventually leads to right ventricular strain and dysfunction.  
Within the pulmonary vasculature, three pathways that are known to be involved 
in pulmonary arterial hypertension include: endothelin, nitric oxide and prostacyclin.  
These pathways play instrumental roles in the regulation of vascular tone.   
Endothelin, a signaling peptide, is an important component in the progression of 
PAH (Archer et al., 2010).  In normal physiology, circulating endothelin helps maintain 
normal vascular tone.  In PAH, levels are elevated in the blood stream and the capacity to 
clear endothelin from the circulation is reduced.  Endothelin exerts its effects by 
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activating two distinct receptors, endothelin A (ETA) and endothelin B (ETB) (Archer et 
al., 2010).  These receptors mediate the pathophysiologic role of endothelin in PAH.  In 
normal physiology, endothelial cells express only the ETB receptor and smooth muscle 
cells express both receptors.  ETA receptors on smooth muscle cells primarily mediate 
vasoconstriction and cellular proliferation.  In PAH, excessive stimulation of ETA 
receptors is thought to cause vasoconstriction, cell proliferation and hypertrophy (Archer 
et al., 2010).  ETB receptors, located on the endothelial cells, mediate endothelin 
dependent vasodilation.  On smooth muscle cells these receptors mediate 
vasoconstriction.  It is hypothesized that under pathologic conditions, smooth muscle cell 
vasoconstriction predominates due to down regulation of ETB on endothelial cells and up 
regulation on smooth muscle cells and the vasodilating response decreases and the 
vasoconstrictive response prevails.  
Nitric oxide (NO) is a diatomic gas that plays an important role in cell signaling 
which stimulates enzyme activity in the vasculature.  Nitric oxide is a vasodilator that 
also inhibits platelet aggregation, thrombosis and inflammation.  Under normal 
conditions, nitric oxide is produced continuously in the vascular endothelium.  Nitric 
oxide diffuses into vascular smooth muscle cells where it binds to and activates guanylate 
cyclase stimulating the synthesis of cGMP, a second messenger for signaling smooth 
muscle relaxation and inhibiting cellular proliferation (Archer et al., 2010).  Rising levels 
of cGMP mediate the effects of nitric oxide.  In PAH, levels of nitric oxide synthase are 
decreased, promoting vasoconstriction and cellular proliferation in vascular smooth 
muscle cells (Pietra et al., 1989).  The availability of nitric oxide is also affected by the 
phosphodiesterase type-5 (PDE-5) enzyme, which degrades cGMP in vascular smooth 
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muscle cells and counteracts the vasodilator effects set in motion by nitric oxide.   
Inhibition of PDE-5 can block this break down of cGMP (Pietra et al., 1989). 
Prostacyclin is the main arachadonic acid metabolite of vascular endothelial and 
smooth muscle cells (Archer et al., 2010).  This potent vasodilator plays a key role in 
maintaining vascular tone.  Prostacyclin is produced in endothelial cells through the 
action of prostacyclin synthase.  Prostacyclin binds to prostaglandin receptors located on 
endothelial and smooth muscle cells leading to a cascade that signals adenylate cyclase to 
produce cAMP.  The second messenger, cAMP inhibits unnecessary platelet aggregation 
and also leads to relaxation of the underlying vascular smooth muscle cells (Archer et al., 
2010).   In PAH, prostacyclins are reduced.  Reduced levels of prostacyclin lead to 
deficient dilatory and anti-proliferative effects.  The addition of prostacyclin has been 
shown to play a pivotal role in the management of PAH (Archer et al., 2010).   
PAH may be heritable or idiopathic, but people with a wide range of conditions 
including those with connective tissue diseases or congenital heart disease are at greater 
risk of developing PAH (Pietra et al., 1989).   As PAH progresses pulmonary vasculature 
resistance increases and cardiac output decreases, which may develop into a severe 
limitation of a patient to perform their daily activity.  Patients with PAH should be 
carefully monitored at regular intervals.  The mean time from symptom onset to diagnosis 
is 2.8 years and left untreated patients with this frequently misdiagnosed rapidly 
progressing have an estimated median survival rate of only 2.8 years (Peacock et al., 
2007).  Prompt intervention in PAH is critical. 
FPAH and APAH (inclusive of Down syndrome and Duchenne muscular 
dystrophy) have specific causes for the increase of arterial pressure.  FPAH results from 
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tightening and/or hardening of the walls of the pulmonary arteries due to inherited 
genetic traits (Vis et al., 2009).  In the case of Down syndrome congenital heart defects 
and the structure of the pulmonary vascular wall increase the pressure (Kim, Ryan, 
Marsboom & Archer, 2011).  APAH related to Duchenne muscular dystrophy results 
from wasting of striated muscle leading to frequent pneumonia and pulmonary edema 
(Saji, 2014). 
From May of 2007 to December of 2008, 704 patients with congenital heart 
defects were studied to identify independent risk factors of PAH in CHD.  The study 
included 319 males and 385 females with a median age of 5 years.  The causes included 
atrial septal defect (n = 185), ventricular septal defect (VSD, n = 452), patent ductus 
arteriosus (PDA, n = 48) and a combinations of the above lesions (n = 19) and 280 
(39.8%) CHD patients had PAH. Logistic regression analysis revealed that age, systemic 
artery systolic blood pressure, VSD, PDA and combined lesions were independent risk 
factors of PAH in CHD (Li et al., 2014). 
Cause of Familial Pulmonary Arterial Hypertension (FPAH): 
 
Also known as heritable pulmonary hypertension (HPAH), FPAH is an example 
of gene mutation with reduced (Ma et al., 2013), (Elliott, 2013) or incomplete (Vis et al., 
2009) penetrance.  Early studies found that the expression of the autosomal dominant 
gene mutation resulted in approximately 20% of individuals developing PAH (Vis et al., 
2009).  The mutation of the gene in question, bone morphogenetic receptor type 2 
(BMPR2), was present in all individuals that developed PAH across studies (Elliott, 
2013).  Among the test groups females were twice as likely to develop PAH suggesting 
sex influence of the disorder (Vis et al., 2009).  Research published as recently as 2013 
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suggest an epistatic effect of BMPR2 mutation on potassium channel subfamily K, 
member 3 (KCNK3) (Ma et al., 2013) and TGF-Beta (single pass serine/threonine kinase) 
receptors (Vis et al., 2009).  The result would be potassium and calcium channelopathy of 
smooth muscle respectively (Ma et al., 2013), (Vis et al., 2009).  Inotropic, squeezing, of 
the smooth muscle lining the arteries increases as a result of intracellular and 
extracellular ion imbalance. 
Additional research has focused on epigenetic mechanisms that influence FPAH.  
Modification of gene function or phenotypic expression without mutation in DNA is the 
definition of epigenetics (Kim et al., 2011).  Two areas of study focus on epigenetic 
consequence of enzyme production.   The first effect centers on the formation of 
superoxide dismutase.  This enzyme changes radicals created during cellular respiration 
to be broken into molecular oxygen or hydrogen peroxide (Xu, Cheng & Du, 2011).  
Without appropriate function of superoxide dismutase cellular respiration byproducts 
result in significant cell damage particular to smooth muscle cells of arteries (Xu et al., 
2011).  The second epigenetic effect involves the formation of nitric oxide synthase 
(Huang, Liang, Zhao, Wu & Zhang, 2013).  Production of nitric oxide from the catalyst 
of L-arginine allows for appropriate control of vascular control and airway tone (Xu et 
al., 2011).   
Cause of Associated Pulmonary Arterial Hypertension (APAH) related to Down 
syndrome and Duchenne muscular dystrophy: 
 
Down syndrome, also known as Trisomy 21, results in a wide range of physical 
and physiological abnormalities.  Affected individuals do not always develop 
cardiovascular problems.  In fact only 45-50% of individuals presenting with Down 
syndrome have subsequent congenital heart defects (CHD) (Kim et al., 2011).  Of those 
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affected, congenital heart defects are predominantly of the septal wall or of the 
atrioventricular valve (Li et al., 2012).  Neonatal surgery to correct CHD is often 
necessary (Li et al., 2012).  Individuals that do and do not receive surgery for CHD are at 
high risk of developing PAH (Sailani et al., 2013) as decreased contractile force of the 
right ventricle affects the pressure in the pulmonary arteries.  Septal wall and 
atrioventricular defects have been related to the expression of two genes.  The CRELD1 
cysteine-rich with EGF-like domains 1 (CRELD1) gene encodes a protein that may 
function as a cell adhesion molecule (Xu et al., 2011).   Additional studies have reported 
that the HEY2 (Hes-Related Family BHLH Transcription 2) gene may have an epistatic 
effect on cardiovascular development (Huang et al., 2013).  A study involving twenty 
individuals with complete AVSD associated with pulmonary hypertension was reported 
in 2009.  Nitric Oxide (NO) and endothelin-1 levels were monitored and compared 
between twelve patients, at 4 to 8 months of age, with Down syndrome and eight patients, 
at 4 to 12 months of age, without Down syndrome.  The study concluded that when 
compared to each other individuals with AVSD associated with pulmonary hypertension 
had no difference in NO or endothelin-1 levels (Saji, 2014).  However, individuals with 
DS did show significant increase in pulmonary vascular resistance and pulmonary artery 
pressure compared to individuals without DS in the comparison (Saji, 2014).  When the 
individuals with DS and individuals without DS both with ASVD related to pulmonary 
hypertension were compared to individuals without ASVD related to pulmonary 
hypertension nitrate and ET-1 levels were significantly higher in the former group (Saji, 
2014). 
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Duchenne muscular dystrophy is a fatal, X-linked disorder (Saji, 2014).  
Individuals affected by the disease suffer from the loss of striated (skeletal and cardiac) 
muscle tissue.  Resultant inability to move and loss of respiratory muscle effort due to the 
progression of the disease can cause frequent pneumonia and pulmonary edema.  In order 
to maintain homeostasis the body increases the pressure in the pulmonary arteries.  In 
DMD, gene mutation results in the production of non-functioning dystrophin (López-
Hernández et al., 2015).  This dystrophin protein is responsible for connecting the muscle 
fiber skeleton to the surrounding structures within the muscle cell (Finsterer, 2006).  A 
study published in 2004 showed strong evidence that NO production was significantly 
decreased in individuals with DMD.  In the study, thirty-one DMD patients with an 
average age of 21.87 years, were compared with twenty-nine patients with other 
neuromuscular disorders average age 40.35 years, along with eleven healthy controls 
average age 30.64 years (Kasai et al., 2004).  Specifically excluding patients taking 
nitrate based medications and patients with active infections the study measured 
nitrite/nitrate levels in the blood.  The results showed significantly lower NO levels in 
individuals with DMD than healthy individuals (2.771+ 2.621 versus 10.405 + 4.240 
gmol/L respectively, p < 0.0001) (Kasai et al., 2004). 
DISSCUSSION 
Pulmonary arterial hypertension is a complex disorder.  Those affected by PAH 
have high rates of mortality directly connected to the disorder.  It is widely accepted that 
the treatment for PAH is largely supportive of cardiopulmonary symptoms (D’Alto et al., 
2013), (Favilli et al., 2015), (Archer et al., 2018).  Advances in medical care and 
treatment have resulted in increased life expectancy for all affected by PAH.  Life 
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expectancy for individuals with co-morbid Down syndrome and PAH has increased over 
time (Saji, 2014), (Vis et al., 2009), (Weijerman et al., 2008).  Quality of life and end 
stage comfort has improved for individuals with Duchenne muscular dystrophy 
(Finsterer, 2006), (Yotsukura, 1988), (Lopez-Hernandez et al., 2015).  Increases in life 
expectancy for this chronic yet still fatal condition, increase the need for critical care in 
hospice and other residential facilities. 
What is the correlation between genetic disorders like DMD and DS with increased 
incidence of PAH? 
 Pulmonary arterial hypertension is a relatively rare disorder with a prevalence of 
between 15-50 cases per million (Peacock et al., 2007).  As previously noted, pulmonary 
hypertension takes on one of five groups.  The first listed group is pulmonary arterial 
hypertension (PAH).  PAH is further divided into four different sub-types.  All too often 
the true cause of PAH in individuals is unfortunately unknown.  When patients present 
with co-morbid conditions such as Down syndrome and Duchenne muscular dystrophy, 
one could draw correlations between the common concomitant pathophysiologic 
processes and the increased likelihood of PAH.  Among the four divisions of PAH, 
associated pulmonary arterial hypertension (APAH) involves the following co-
morbidities: connective tissue disease, HIV infection, portal hypertension, congenital 
heart disease and schistosomiasis (Saji, 2014).  
 The physical and physiologic changes associated with Down syndrome vary 
widely.  Sadly, congenital heart defects result in an overwhelming number of deaths in 
individuals diagnosed with Down syndrome. In a 2003 study of 182 children diagnosed 
with Down syndrome in the Netherlands, 12.2% of subjects died within 12 hours of birth 
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and an additional 3.67% died within 10 days of birth due to complications of congenital 
heart defects (Weijerman et al., 2008).  Not all individuals with Down syndrome 
experience congenital heart defects, in fact, 45-50% of the diagnosed population are free 
from CHD (Kim et al., 2011).  A reverse analysis of that statistic would suggest that 50-
55% of individuals with Down syndrome do suffer from a form of CHD.   The majority 
of CHD in Down syndrome are related to septal wall and atrioventricular valve defects 
(Li et al., 2012).  The inborn defects of the heart most associated with PAH are 
coincidentally those of a ventricular septal defect (VSD) or patent ductus arteriosus 
(PDA) are identified as independent risk factors in PAH.  From May of 2007 to 
December of 2008, 704 patients with congenital heart defects were studied to 
identify independent risk factors of PAH in CHD.  Logistic regression analysis revealed 
that age, systemic artery systolic blood pressure, VSD, PDA and combined lesions were 
independent risk factors of PAH in CHD (Li et al., 2014).  Although individuals with 
Down syndrome were not identified in the study, one could draw a correlation between 
its population and the incidence of specific CHD in Down syndrome.   
 PAH is the result of pathogenesis in one of three or a combination of three 
pathways: endothelin, nitric oxide and prostacyclin.  Duchenne muscular dystrophy 
progresses with muscle wasting and connective tissue disorders.  These processes result 
in eventual dystrophy of the diaphragm and pneumonia.  Evidence has been presented 
that would suggest that DMD would show decreased levels of nitric oxide and 
prostacyclin with increased levels of endothelin.  A study comparing thirty-one 
individuals with DMD and eleven healthy individuals a significant correlation (r = -
0.384, p = 0.0391) between plasma nitric oxide levels and ejection fraction measured by 
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echocardiogram in the DMD group (Kasai et al., 2004).  The finding suggests that there is 
a significant decrease in production of nitric oxide as part of the disease process of DMD.  
As described earlier, decreased levels of nitric oxide have a direct effect on prostacyclin 
and a converse effect on endothelin.  As the genetic disorder progresses, seemingly all 
individuals affected by DMD develop pulmonary hypertension.  Specifically, a study of 
eight individuals with advanced development of DMD were evaluated by right heart 
catheterization.  A mPAP of > 20 mmHg was noted in all subjects while five of the eight 
had a mean pulmonary arterial pressure of > 40 mmHg (Yotsukura, Miyagawa, Tsuya, 
Ishihara & Ishikawa, 1988).  Although the study was very limited it does suggest that 
pulmonary hypertension is inevitable in DMD and that PAH is highly likely. 
What has current and existing research shown in the understanding of pulmonary 
arterial hypertension? 
PAH encompasses a number of disorders with somewhat varied epidemiology, 
depending on the particular PAH subgroup referenced.  Pulmonary hypertension is 
actually relatively common; however, most patients with pulmonary hypertension do not 
have PAH.  PAH is a rare disorder with overall prevalence of 15-50 cases per million 
(Peacock et al., 2007). In certain high risk populations, the prevalence of PAH is much 
higher: systemic sclerosis 12%, sickle cell disease/hemolytic anemia 4% and HIV 
infection 0.5% (Archer et al., 2010).  Overall PAH is two to four-fold more common in 
women vs. men (Peacock et al., 2007).  Though symptoms can occur at any age, the 
disease most commonly begins showing symptoms in the fourth or fifth decade of life.  
Idiopathic PAH makes up nearly 50% of the cases of PAH with associated PAH 
accounting for the remainder. 
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Although the exact molecular basis of the PAH remains to be elucidated, several 
molecular pathways have been implicated in the pathophysiology of PAH (Archer et al., 
2010).  The initial inciting event in PAH is felt to be pulmonary endothelial cell injury. 
This in turn triggers a molecular cascade which eventually results in a distal small vessel 
arteriopathy characterized by medial hypertrophy, intimal proliferation and thickening, 
microthrombi formation, and ultimately plexiform lesions (Pietra et al., 1989). 
The Pulmonary Hypertension Association summarized the pathophysiologic 
pathways of PAH at its 2017 symposium: 
 Nitric oxide (NO): endogenous pulmonary vasodilator which also 
possesses anti-proliferative properties and a relative deficiency of 
endothelial NO in the pulmonary vasculature may be one mechanism 
which contributes to the development of PAH. 
 Endogenous prostacyclins: systemic and pulmonary vasodilators, 
anti-proliferative agents and also have antithrombotic/antiplatelet 
effects. Relative deficiency or down-regulation of endogenous 
prostacyclin may contribute to the development of PAH. 
 Endothelin-1: an endogenous vasoconstrictor and up-regulation of 
endogenous endothelin-1 may also contribute to the pathogenesis of 
PAH. (paragraph 9, PHA Online University Diagnosis and Treatment) 
The small vessel arteriopathy in PAH leads to a progressive rise in RV afterload and 
pulmonary vascular resistance (PVR). As a result, the RV undergoes remodeling changes 
including right ventricular hypertrophy, dilatation and finally dysfunction. If PAH is left 
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untreated, right ventricular failure will ultimately result in patients experiencing syncope, 
angina, edema and abdominal distention (Favilli et al., 2015).  Right ventricular failure is 
the most common cause of death in patients with PAH (Sitbon and Morrell, 2012). 
 Most recently, there have been studies identifying a specific protein that is linked 
to the development of PAH. PDLIM5 protein is produced in the smooth muscle cells of 
the pulmonary artery (Zhou, Chen and Raj, 2015).  Within the past year the American 
Lung Association has begun investigating the effect hypoxia has on the PDLIM5 
expression.  Of particular note is the suppressive effect PDLIM5 plays on the activation 
of a downstream protein SMAD2/3 which are responsible for cell signaling in smooth 
muscle (Ousterout et al., 2015).  This study is scheduled to conclude in 2019. 
What is the recommended, evidence based treatment modality for PAH specific to 
DMD and DS? 
 There are no specific plans for the treatment of PAH in DMD or DS.  Care for 
pulmonary hypertension in general involves volume maintenance, appropriate 
immunization and oxygen therapy (Favilli et al., 2015).  There are specific treatment 
plans written for each type of pulmonary hypertension, however, the plan for APAH, 
under which DMD and DS fall, is largely reserved for the advanced stages of the disease.  
As there is currently no way to treat the underlying genetic disorders, the care remains 
supportive.  Surgical correction of congenital heart defects is a necessity prior to further 
treatment (Saji, 2014).  At this time medical treatment is based by and large on the 
opinion of experts rather than clinical trial or study.  Again, the 5th World Symposium on 
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Pulmonary Hypertension, Nice, France, February 27 to March 1, 2013 developed the 
algorithm shown in Figure 1. 
 
Figure 1. Flow Chart of PAH Evidence-based Treatment Algorithm: Journal of the 
American College of Cardiology by AMERICAN COLLEGE OF CARDIOLOGY Reproduced with 




Differentiation into class I-IV is based off of patient diagnosis with pulmonary 
hypertension by right heart catheterization and by ability to carry out physical activity 
(Favilli et al., 2015).   
The World Health Organization (WHO) functional classification for pulmonary 
hypertension is as follows: 
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 Class I- Patients with pulmonary hypertension but without resulting 
limitations of physical activity.  Ordinary physical activity does not 
cause undue dyspnea or fatigue, chest pain, or syncope. 
 Class II- Patients with pulmonary hypertension resulting in slight 
limitation of physical activity.  They are comfortable at rest.  Ordinary 
physical activity causes undue dyspnea or fatigue, chest pain, or near 
syncope. 
 Class III- Patients with pulmonary hypertension resulting in marked 
limitation of physical activity.  They are comfortable at rest.  Less than 
ordinary activity causes undue dyspnea or fatigue, chest pain, or near 
syncope. 
 Class IV- Patients with pulmonary hypertension with inability to carry 
out any physical activity without symptoms.  These patients manifest 
signs of right-heart failure.  Dyspnea and/or fatigue may even be 
present at rest.  Discomfort is increased by any physical activity. (table 
2, p. 1791) 
Critical weight is placed on the individual patient’s ability to be involved in their 
care.  In the case of patients with DMD or DS concomitant PAH treatment become 
problematic.  As classification is based, in part, on physical activity level, emphasis is 
placed on the patient’s ability to communicate effectively.  This may be a limiting factor 
as PAH presents as a late stage of development in DMD.  Activity level will be 
significantly lowered at this point due to the progressively degenerative nature of the 
disorder.  Furthermore, the ability of to communicate symptoms and activity level may be 
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diminished within the population of individuals with Down syndrome as well.  
Successful recognition and treatment of PAH in DMD and DS would require concerted 
effort by care providers including: the patient, family members, healthcare workers, 
community integration personnel, teachers, etc...  
Among individuals with Duchenne muscular dystrophy and Down syndrome with 
co-morbid pulmonary arterial hypertension (PAH) has early recognition and 
treatment through genetic discovery lead to a statistically significant increase in life 
expectancy versus previously undiagnosed or unrecognized PAH? 
There is no direct evidence to suggest that there has been an increase in life 
expectancy with early recognition and treatment of PAH through genetic discovery 
amongst individuals with DMD and DS.  Pulmonary arterial hypertension remains a 
complex disease process.  Those affected by PAH have high rates of mortality directly 
connected to the disorder.  As it stands, the treatment for PAH is largely supportive of 
cardiopulmonary symptoms and is largely carried out by cardiologists and 
pulmonologists with significant training and experience.  Advances in medical care and 
treatment have resulted in increased life expectancy for all affected by PAH.  Likewise, 
life expectancy for individuals with co-morbid Down syndrome and PAH alone has 
increased from 12 to 60 years of age since the 1940’s (Vis et al., 2009).  The application 
of clinical practices would seem to benefit all groups diagnosed with the disorder.  
Increases in life expectancy for this chronic yet still fatal condition increase the need for 
critical care in hospice and other residential facilities.   
Research finding the genetic cause of specific types of PAH is necessary in 
locating the cure for the spectrum disorder.  Identification of gene mutation and 
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epigenetic influence has provided strong foundations for continued research.  New 
research should be based on treatment of existing illness, screening for prevention and 
cure in order to improve quality of life. 
 
CLINICAL APPLICATION 
 The incidence of pulmonary arterial hypertension is increased among populations 
of individuals with Duchenne muscular dystrophy and Down syndrome.  Having an 
understanding of the pathophysiology of the disease will help patients and families 
understand its progression.   A primary care provider in a rural area could be called upon 
to act as the intermediary between a cardiologist or pulmonologist in the treatment of 
such individuals.  Furthermore, the PCP is instrumental in providing screening and 
wellness services to this specific population.  Developing a thorough familiarity with 
individual patients will help tease out or recognize changes in activities of daily living.  
Advances in research prove the need to continually develop knowledge and skill.   
 DMD is a progressive, fatal disease.  The disease affects the cardiopulmonary 
circuit as a late stage.  53-90% of the mortality associated with DMD is from respiratory 
failure (Finsterer, 2006).  Although the prognosis is an inevitability measures can be 
applied to improve quality of life.  The PCP can help guide the patient and family 
through these practices.  Advice concerning surgery to correct associated scoliosis, 
noninvasive ventilatory management, nutritional support, and expiratory muscle training 
could prove instrumental in maintaining cardiopulmonary function for longer periods of 
time (Finsterer, 2006).  Management of medications like corticosteroids, PDE-5 
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inhibitors and endothelin receptor antagonists will help reduce precapillary pulmonary 
hypertension (Yotsukura et al., 1988).   
 The effects of DS do not necessarily lead to the untimely prognosis of DMD.  
Because of its pathogenesis the effects of PAH are recorded much earlier in the disorder 
particularly in the case of congenital heart defects associated with DS.   The vasculature 
of individuals with DS is markedly decreased in caliber compared to individuals without.  
This is particularly noted in the capillaries of the pulmonary circuit resulting in the 
increase in pulmonary arterial pressure (Saji, 2014).  Understanding the need for early 
correction of CHD in individuals with DS will hopefully be recognized before delivery or 
soon thereafter, a PCP could easily be part of that conversation.  Moreover, knowing that 
the vasculature narrows with time regardless of surgical CHD correction will help an 
individual understand the importance of medication management. 
 Developing a health and wellness routine for individuals who are likely to 
develop or currently afflicted by PAH would be under the purview of the PCP.  The need 
to keep immunizations up to date in fragile populations should be nothing new.  The 
understanding of profound effect influenza or pneumonia would have on an individual 
with PAH should increase the investment in prophylactic measures.  Beyond having a 
deeper insight for vaccination schedules, the PCP would need to have an intuitive 
appreciation for the decreases in activities of daily living (ADLs) for this specific 
population.  Teasing out the nature or cause of decrease in ADLs can help differentiate 
progression of PAH from progression of DMD or DS.  This familiarity is much more 
likely in the primary care setting rather than the specialty.  Indeed, the personal 
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relationship that is developed in the primary care setting creates a situation that allows for 
better medication and interventional therapies. 
 The primary care provider needs to be involved in the coordination of care of the 
individual with DMD or DS with concomitant PAH.  Input from family, friends, teachers, 
care providers, case managers, social workers, physical/occupational and respiratory 
therapists is invaluable.  Working to share ideas and observations is a vital step in the 
cohesive plan management of patient care.  Attendance at multi-disciplinary team 
meetings would seem obvious. 
 Finally, the ever changing nature of this topic further solidifies the need to 
continue growth and development of knowledge and skill.  In the course of researching 
this topic there have been two studies that have caused changes in what was known about 
PAH.  As discussed, a pivotal study is underway and scheduled to be completed in 2019.  
The knowledge that clinical practice generally lags behind research by ten years may 
sound discouraging, however, personal devotion to improvement can change that. 
 Research to help find the genetic cause of specific types of PAH is necessary in 
locating the cure for the spectrum disorder.  Identification of gene mutation and 
epigenetic influence has provided strong foundations for continued research.  New 
research should be based on: treatment of existing illness, screening for prevention and 
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